Wells Fargo & Company MN decreased its holdings in shares of Allergan plc (NYSE:AGN) by 4.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,781,198 shares of the company’s stock after selling 91,768 shares during the quarter. Wells Fargo & Company MN’s holdings in Allergan were worth $339,282,000 as of its most recent SEC filing.
Several other hedge funds have also bought and sold shares of AGN. Flagship Harbor Advisors LLC purchased a new position in shares of Allergan in the 2nd quarter worth $129,000. Gradient Investments LLC raised its position in Allergan by 747.5% in the third quarter. Gradient Investments LLC now owns 678 shares of the company’s stock valued at $129,000 after purchasing an additional 598 shares during the period. Kaizen Advisory LLC raised its position in Allergan by 156.2% in the second quarter. Kaizen Advisory LLC now owns 830 shares of the company’s stock valued at $138,000 after purchasing an additional 506 shares during the period. Migdal Insurance & Financial Holdings Ltd. raised its position in Allergan by 3,193.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 988 shares of the company’s stock valued at $165,000 after purchasing an additional 958 shares during the period. Finally, Aries Wealth Management purchased a new position in Allergan in the second quarter valued at about $202,000. Institutional investors and hedge funds own 77.55% of the company’s stock.
Several research analysts have commented on AGN shares. Wells Fargo & Co reissued a “buy” rating on shares of Allergan in a research report on Saturday, September 15th. Raymond James reissued a “buy” rating and issued a $232.00 price objective (up from $211.00) on shares of Allergan in a research report on Monday, September 17th. Zacks Investment Research lowered Allergan from a “hold” rating to a “sell” rating in a research report on Wednesday, October 3rd. Cantor Fitzgerald reissued a “hold” rating and issued a $180.00 price objective on shares of Allergan in a research report on Friday, September 14th. Finally, ValuEngine raised Allergan from a “strong sell” rating to a “sell” rating in a research report on Friday, September 21st. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and eighteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $210.18.
Shares of NYSE AGN opened at $165.21 on Wednesday. Allergan plc has a 1 year low of $142.81 and a 1 year high of $197.00. The stock has a market cap of $54.99 billion, a PE ratio of 10.10, a price-to-earnings-growth ratio of 1.29 and a beta of 1.31. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.78 and a current ratio of 0.92.
Allergan (NYSE:AGN) last posted its quarterly earnings results on Tuesday, October 30th. The company reported $4.25 EPS for the quarter, topping the Zacks’ consensus estimate of $4.04 by $0.21. The business had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.89 billion. Allergan had a return on equity of 8.44% and a net margin of 14.50%. The company’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same period last year, the firm earned $4.15 earnings per share. Equities research analysts anticipate that Allergan plc will post 16.42 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 14th. Investors of record on Tuesday, November 13th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Friday, November 9th. This represents a $2.88 dividend on an annualized basis and a yield of 1.74%. Allergan’s dividend payout ratio (DPR) is 17.61%.
COPYRIGHT VIOLATION NOTICE: “Wells Fargo & Company MN Has $339.28 Million Stake in Allergan plc (AGN)” was first posted by WKRB News and is owned by of WKRB News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.wkrb13.com/2018/11/07/wells-fargo-company-mn-has-339-28-million-stake-in-allergan-plc-agn.html.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.
See Also: Do You Need a Fiduciary?
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.